130 related articles for article (PubMed ID: 38624096)
1. Endocrinological and metabolic profile of Gaucher disease patients treated with enzyme replacement therapy.
Kilic A; Emecen Sanli M; Ozsaydı Aktasoglu E; Gokalp S; Biberoğlu G; Inci A; Okur I; Suheyl Ezgu F; Tumer L
J Pediatr Endocrinol Metab; 2024 May; 37(5):413-418. PubMed ID: 38624096
[TBL] [Abstract][Full Text] [Related]
2. Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy.
van Dussen L; Hendriks EJ; Groener JE; Boot RG; Hollak CE; Aerts JM
J Inherit Metab Dis; 2014 Nov; 37(6):991-1001. PubMed ID: 24831585
[TBL] [Abstract][Full Text] [Related]
3. The role of high density lipoprotein in Type 1 Gaucher disease.
Watad S; Abu-Saleh N; Yousif A; Agbaria A; Rosenbaum H
Blood Cells Mol Dis; 2018 Feb; 68():43-46. PubMed ID: 27876360
[TBL] [Abstract][Full Text] [Related]
4. Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study.
Zimmermann A; Grigorescu-Sido P; Rossmann H; Lackner KJ; Drugan C; Al Khzouz C; Bucerzan S; Naşcu I; Zimmermann T; Leucuţa D; Weber MM
J Inherit Metab Dis; 2013 May; 36(3):555-63. PubMed ID: 22976766
[TBL] [Abstract][Full Text] [Related]
5. Enzyme replacement and substrate reduction therapy for Gaucher disease.
Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
[TBL] [Abstract][Full Text] [Related]
6. Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases.
Ivanova MM; Changsila E; Iaonou C; Goker-Alpan O
PLoS One; 2019; 14(1):e0210617. PubMed ID: 30633777
[TBL] [Abstract][Full Text] [Related]
7. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
8. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
9. Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease.
Ivanova MM; Dao J; Kasaci N; Adewale B; Nazari S; Noll L; Fikry J; Sanati AH; Goker-Alpan O
PLoS One; 2021; 16(10):e0247211. PubMed ID: 34695170
[TBL] [Abstract][Full Text] [Related]
10. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.
Elstein D; Mellgard B; Dinh Q; Lan L; Qiu Y; Cozma C; Eichler S; Böttcher T; Zimran A
Mol Genet Metab; 2017 Sep; 122(1-2):113-120. PubMed ID: 28851512
[TBL] [Abstract][Full Text] [Related]
11. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
Mistry PK; Weinreb NJ; Kaplan P; Cole JA; Gwosdow AR; Hangartner T
Blood Cells Mol Dis; 2011 Jan; 46(1):66-72. PubMed ID: 21112800
[TBL] [Abstract][Full Text] [Related]
12. Could enzyme replacement therapy promote immune tolerance in Gaucher disease type 1?
Matta MC; Vairo F; Torres LC; Schwartz I
Blood Cells Mol Dis; 2018 Feb; 68():200-202. PubMed ID: 28029576
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
Elstein D; Mehta A; Hughes DA; Giraldo P; Charrow J; Smith L; Shankar SP; Hangartner TN; Kunes Y; Wang N; Crombez E; Zimran A
Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
[TBL] [Abstract][Full Text] [Related]
14. [Effect of enzyme replacement therapy on lipid profile in patients with Gaucher's disease].
Alfonso P; Cenarro A; Pérez-Calvo JI; Puzo J; Giralt M; Giraldo P; Pocoví M
Med Clin (Barc); 2003 May; 120(17):641-6. PubMed ID: 12747811
[TBL] [Abstract][Full Text] [Related]
15. Generation of osteoclasts from type 1 Gaucher patients and correlation with clinical and genetic features of disease.
Reed MC; Bauernfreund Y; Cunningham N; Beaton B; Mehta AB; Hughes DA
Gene; 2018 Dec; 678():196-206. PubMed ID: 30099023
[TBL] [Abstract][Full Text] [Related]
16. Neuronopathic Gaucher disease presenting with microcytic hypochromic anemia.
Kim EA; Lim YT; Hah JO; Sohn YB; Kim YK; Choi JH; Kim SY; Jang KM; Ahn J; Lee JM
Int J Hematol; 2019 Mar; 109(3):361-365. PubMed ID: 30456712
[TBL] [Abstract][Full Text] [Related]
17. Long-term bone mineral density response to enzyme replacement therapy in a retrospective pediatric cohort of Gaucher patients.
Ciana G; Deroma L; Franzil AM; Dardis A; Bembi B
J Inherit Metab Dis; 2012 Nov; 35(6):1101-6. PubMed ID: 22441841
[TBL] [Abstract][Full Text] [Related]
18. Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease.
Donald A; Björkvall CK; Vellodi A; ; Cox TM; Hughes D; Jones SA; Wynn R; Machaczka M
Orphanet J Rare Dis; 2022 Jun; 17(1):234. PubMed ID: 35717194
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, open-label, phase III study of Abcertin in Gaucher disease.
Lee BH; Abdalla AF; Choi JH; Beshlawy AE; Kim GH; Heo SH; Megahed AMH; Elsayed MAL; Barakat TEM; Eid KMAE; El-Tagui MH; Mahmoud MMH; Fateen E; Park JY; Yoo HW
Medicine (Baltimore); 2017 Nov; 96(45):e8492. PubMed ID: 29137040
[TBL] [Abstract][Full Text] [Related]
20. Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease.
Nascimbeni F; Dalla Salda A; Carubbi F
Blood Cells Mol Dis; 2018 Feb; 68():74-80. PubMed ID: 27839982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
